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The Home Office has recently published estimates which, for first time, provide a “robust 
national estimate” of the number of problematic drug users (PDU) in England.  The 
2004/05 and 2005/06 estimates are the highest estimates ever produced for England and 
coincide with the highest ever Government annual expenditure on combating illicit drug 
use. This paper reviews a range of data sources that indicate a downwards trend in 
problematic drug use in recent years. The validity of the estimates is important for drug 
policy and the paper considers the implications of both increasing and decreasing levels 
of problematic drug use. 
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The Home Office has recently published estimates of the number of problematic drug 




.  The first study report states that the 
method used “provides for the first time a robust national estimate of this important target 
group”.  Previous estimates are said to be less robust because they “had very wide 
confidence intervals within which the true estimate might lie”.  The 2004/05 and 2005/06 
estimates are the highest estimates ever produced for England and coincide with the 
highest ever annual UK Government’s direct annual expenditure on combating illicit 




However, robustness is not just a matter of confidence intervals but of the validity of the 
data and methods which underlie the estimates. The implication of the 2004/05 and 
2005/06 estimates is that problematic drug use is at an all time high.  Elsewhere the 
authors of these estimates discuss a scenario where problematic drug use in the UK may 
continue to increase to over 1 million by 2025
4
. However, other data sources, described 
below, indicate a downwards trend in problematic drug use in recent years. 
 
The recent PDU estimates are based on two statistical techniques; the capture recapture 
method (CRM) and (to a lesser extent) the multiple indicator method (MIM). Both 
 4 
methods are indirect ways of estimating prevalence and rely on data on known drug 
users
5,6
. Indirect methods are generally used for PDU, as direct methods such as 
population surveys have obvious limitations for this group.   
 
CRM involves examining the overlap between lists of drug users whose identifiers are 
recorded by agencies such as treatment centres or the police. Essentially, the lower the 
level of overlap, the higher the estimate.  Thus accurate identification of individuals is 
essential.  More sophisticated versions involving multiple samples have also been 
developed in order to overcome the stringent assumptions which are required when only 
two-samples are used. MIM is a form of multiple regression analysis in which drug 
indicators are used to impute estimates in areas where the number of users is unknown. In 
simple terms, as the level of drug indicators increase, so to does the prevalence estimate. 
 
For CRM to produce valid estimates cases should have equal ‘catchability’ in each source 
and be uniquely matched among the various data sources. MIM assumes that there is a 
linear relationship between drug indicators and prevalence and that this relationship is the 
same in all areas.  The underlying robustness or otherwise of these models, therefore 
depends on whether these assumptions are met. 
 
In practice these assumptions are difficult to verify.  An alternative approach to 
evaluating robustness is to consider the criterion validity of the estimates. Criterion-
related validity includes “any validity strategies that focus on the correlation of the 
 5 





One way of assessing the criterion validity of the estimates is to compare trends in 
prevalence estimates and other measures of problematic drug use. The estimates would 
have criterion validity if the magnitude and direction of change in PDU prevalence 
estimates were similar to the change in drug indicators. 
 











.  Three drug indicators have data over the necessary time scale. These are a) the 
British Crime Survey
11
, b) the number of drug related deaths
12
 and c)the number of 
hospital admissions that are due to drug abuse
13
.  All three of these indicators are 
potentially less biased than, for example, the number of drug offences which is more 
likely to be influenced by policy
14
. For the BCS, the most appropriate indicator is level of 
class A drug use in the last month. 
 
Table 1 shows that between 1996 and 2001/02, the PDU estimate increased by 27.6%. 
The average increase in the three indicators was 16.2%. Between 2001/02 and 2004/05, 
the PDU estimate increased by 13.8% while the average decrease in the three indicators 
was 6.4%.  
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Table 1.  Drug indicators and EU/Home Office PDU estimates 
Data 1996 2001/02002 2004/2005 
% change  
1996-2001/02 
% change  
2001/02-
2004/05 
N of Hospital Episodes 
in England 
due to drug abuse 
7,509 8,767 8,684 +16.8 -0.9 
BCS: Class A use in 
last month 
(Est. N of users in 
England and Wales) 
388,941 551,000 473,000 +41.7 -14.2 
Number of drug related 
deaths in England 
2,721 2,898 2,598 +6.5 -10.4 
Average change in 
indicators 
      +16.2 -6.4 
EU/Home Office PDU 
median estimate for 
England 
225,403 287,670 327,447 +27.6 +13.8 
Note: the 1996 and 2001 definition of problematic drug use was ‘current use of illicit opiates, crack-cocaine or 
benzodiazepines’; 2005 definition was restricted to “use of opiates and/or the use of crack cocaine”. 
 
The direction of change for all drug indicators between 1996 and 2001/02 is in the same 
direction as the PDU estimates. In contrast between 2001/02 and 2004/05, the PDU 
estimate increased while the three drug indicators declined.  
 
There is also further evidence that PDU has declined in recent years.  The Home Office’s 
Drug Harm Index (DHI) mirrors the indicators reported here. The DHI incorporates 
measures of the harms that individuals and society suffer due to drug-related crime, the 
health impacts arising from drug abuse, and the impact of drug use and dealing on 
communities. This is achieved by using readily available published data for each of the 
harms, which are then combined into a single-figure time-series index
15
. In 1998 the 





If the DHI trend is applied to the PDU estimates, using the 2001/02 estimate as the 
baseline, the 2005/05 figure would be 200,000, i.e. 40% lower than the Home Office 
estimate. As this estimate is far outwith the confidence interval of 325,945 – 343,424, the 
implications are either that the analysis presented here is faulty or that the data on which 
the 2004/05 estimates are based are not suitable for the statistical methods used. 
 
The validity of the estimates is important for drug policy. If the 2004/05 estimates are 
valid they suggest that efforts to combat problematic drug use from 2001 to 2005 have 
not been successful, since the estimated number of problematic drug users has increased 
by 14% compared to the 2001/02 estimate. It is possible that increasing levels of PDU 
could coexist with decreasing levels of drug indicators if, for example, harm reduction 
polices have been effective in reducing the number of drug related deaths. However, one 
of the authors of the recent estimates has specifically criticised harm reduction policies
17
 
and has stated that they have “failed”
18
.  An alternative scenario, would be that the actual 
PDU level is significantly lower than the published estimate which is therefore not as 
“robust” as has been claimed.  A recent Swiss study reported that heroin substitution 
programmes with methadone or buprenorphine) are associated with declining incidence 
of heroin use in treatment in Switzerland
19
 perhaps because the medicalisation of drug 
addiction has changed the image of heroin such that it is no longer seen as an attractive 
drug of choice for many young people. Although the authors of the Swiss study are 
careful to avoid claiming that there is a direct causal association, their detailed analysis is 
at least consistent with this hypothesis.  The analysis presented in the current paper is 
similarly consistent, but the cultural context of drug use in the UK is very different and 
 8 
further analysis is required to evaluate the impact of different prevention and treatment 
strategies. 
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While a recent Home Office study has indicated that problematic drug misuse in the 
England is at an all time high, this paper reviews a range of data which indicate that 
challenges that problematic drug misuse may well be declining To the best of our 
knowledge the perception of ever increasing levels of problematic drug misuse is rarely, 
if ever, challenged in the public health arena.  As over £1 billion of public money is being 
allocated to combat illicit drug use, policy makers should carefully consider the true 
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